Prostate Cancer

Screening Cuts Risk of Advanced PCa

Biennial PSA screening decreases the likelihood of being diagnosed with metastatic prostate cancer, but nearly doubles the chance of being diagnosed with prostate cancer of any type, a Swedish sudy found.

Fast Track for New Prostate Cancer Therapy

The FDA has assigned priority review status to the Biologics License Application for Provenge (sipuleucel-T), an investigational immunotherapy for asymptomatic, metastatic, androgen-independent (also known as hormone refractory) prostate cancer.

Oral Platinum Analogue Looks Good

NEW YORK—Satraplatin, the first oral platinum analogue, is among the more promising second-line treatments for hormone-refractory prostate cancer (HRPC), a researcher said here at the 2006 Chemotherapy Foundation Symposium.

Drug Is Beneficial In Some PCa Cases

NEW YORK CITY—Results of the largest clinical trial ever conducted in non-metastatic prostate cancer suggest that bicalutamide (Casodex) added to standard care may improve overall survival in men with locally advanced disease undergoing radiotherapy.

Next post in Prostate Cancer